BioVie to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Virtual Summit
BioVie Inc. (NASDAQ: BIVI) announced its management team's participation in the Oppenheimer Fall Healthcare Life Sciences & MedTech Virtual Summit on September 22, 2021, at 12:25 p.m. EST. This conference will provide an update on BioVie’s innovative drug therapies targeting neurodegenerative disorders and advanced liver disease. BioVie is currently evaluating BIV201 for refractory ascites and plans to initiate a Phase 3 study for hepatorenal syndrome. Additionally, the company is conducting a pivotal study for NE3107, aimed at treating Alzheimer's disease, with results expected in late 2022.
- None.
- None.
SANTA MONICA, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurodegenerative disorders and advanced liver disease, today announced the participation of its management team in the Oppenheimer Fall Healthcare Life Sciences & MedTech Virtual Summit September 22, 2021.
Details on the conference can be found below.
Oppenheimer Fall Healthcare Life Sciences & MedTech Virtual Summit
Format: BioVie Update & Overview
Date: Wednesday September 22, 2021
Presentation time: 12:25 p.m. EST
Webcast: https://wsw.com/webcast/oppenheimer16/bivi/2769630
An archived webcast will also be accessible in the Investors section of the company’s website at www.bioviepharma.com.
About BioVie
BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing transformative therapies to overcome unmet medical needs in chronic debilitating conditions. In liver disease, the Company’s Orphan drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status, is being evaluated in a US Phase 2 study for the treatment of refractory ascites with top-line results expected in early 2022. The Company is also planning a pivotal Phase 3 study of BIV201 in the treatment of hepatorenal syndrome-acute kidney injury (HRS-AKI) in 2022. BIV201 is administered as a patent-pending liquid formulation. The active agent is approved in about 40 countries for related complications of advanced liver cirrhosis but is not available in the US or Japan. In neurodegenerative disease, BioVie acquired the assets of NeurMedix Inc., including NE3107 that inhibits inflammatory activation of ERK and NFB (e.g. TNF transcription) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions (e.g. insulin signaling and neuron growth and survival). Both are drivers of Alzheimer’s and Parkinson’s diseases. The Company is conducting a potentially pivotal Phase 3 randomized, double blind, placebo controlled, parallel group, multicenter study to evaluate NE3107 in subjects who have mild to moderate Alzheimer's disease (NCT04669028). An estimated six million Americans suffer from Alzheimer’s. BioVie has initiated this study and is targeting primary completion in late 2022. A Phase 2 study of NE3107 in Parkinson’s disease is planned to start later this year, and related compounds have additional potential to treat certain cancers. NE3107 is patented in the United States, Australia, Canada, Europe and South Korea. For more information, visit http://www.biovieinc.com/.
Forward-Looking Statements
This press release contains forward-looking statements, which may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein due to the Company's ability to successfully raise sufficient capital on reasonable terms or at all, available cash on hand and contractual and statutory limitations that could impair our ability to pay future dividends, our ability to complete our clinical studies and to obtain approval for our product candidates, to successfully defend potential future litigation, changes in local or national economic conditions as well as various additional risks, many of which are now unknown and generally out of the Company's control, and which are detailed from time to time in reports filed by the Company with the SEC, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law.
For Investor Relations Inquiries:
| Contact: Bruce Mackle Managing Director LifeSci Advisors, LLC bmackle@lifesciadvisors.com | |
FAQ
When is BioVie participating in the Oppenheimer Summit?
What time will BioVie present at the Oppenheimer Summit?
What are BioVie’s key drug candidates mentioned in the press release?
What is the focus of BioVie’s drug development?
When can we expect top-line results for BIV201?
What phase is BioVie’s study for NE3107?
What is the stock symbol for BioVie?
